H
Hillel Panitch
Researcher at University of Vermont
Publications - 75
Citations - 8448
Hillel Panitch is an academic researcher from University of Vermont. The author has contributed to research in topics: Multiple sclerosis & Glatiramer acetate. The author has an hindex of 40, co-authored 75 publications receiving 8109 citations. Previous affiliations of Hillel Panitch include Veterans Health Administration & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker,Paul O'Connor,Mark S. Freedman,Peter A. Calabresi,Jack P. Antel,Jack H. Simon,Stephen L. Hauser,Emmanuelle Waubant,Timothy Vollmer,Hillel Panitch,Jiameng Zhang,Peter Chin,Craig H. Smith +12 more
TL;DR: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS).
Journal ArticleDOI
Treatment of multiple sclerosis with gamma interferon Exacerbations associated with activation of the immune system
TL;DR: Results show that systemic administration of gamma interferon has pronounced effects on cellular immunity in MS and on disease activity within the CNS, suggesting that the attacks induced during treatment were immunologically mediated.
Journal ArticleDOI
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Hillel Panitch,Douglas S. Goodin,Gordon S. Francis,P Chang,Patricia K. Coyle,Paul O'Connor,Edward Monaghan,David K.B. Li,Brian G. Weinshenker +8 more
TL;DR: IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Journal ArticleDOI
Differential diagnosis of suspected multiple sclerosis: a consensus approach
David Miller,Brian G. Weinshenker,Massimo Filippi,Brenda Banwell,Jeffrey A. Cohen,Mark S. Freedman,SL Galetta,Michael Hutchinson,Richard T. Johnson,Ludwig Kappos,Jun Ichi Kira,Fred D. Lublin,Henry F. McFarland,Xavier Montalban,Hillel Panitch,J. R. Richert,Stephen C. Reingold,Chris H. Polman,Chris H. Polman +18 more
TL;DR: This paper developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases.
Journal ArticleDOI
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,R. P. Lisak,Lawrence W. Myers,Hillel Panitch,J. W. Rose,R. B. Schiffer,Timothy Vollmer,Leslie P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: The clinical benefit of glatiramer acetate for both the relapse rate and for neurologic disability was sustained at the end of the extension trial.